Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.45 USD
Change Today -0.15 / -1.97%
Volume 101.5K
STAA On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

staar surgical co (STAA) Snapshot

Open
$7.61
Previous Close
$7.60
Day High
$7.78
Day Low
$7.41
52 Week High
09/12/14 - $11.88
52 Week Low
01/27/15 - $4.84
Market Cap
296.5M
Average Volume 10 Days
154.7K
EPS TTM
$-0.19
Shares Outstanding
39.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STAAR SURGICAL CO (STAA)

Related News

No related news articles were found.

staar surgical co (STAA) Related Businessweek News

No Related Businessweek News Found

staar surgical co (STAA) Details

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company offers implantable collamer lenses (ICL) comprising Visian ICL to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also provides invasive intraocular lenses (IOL) that include aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece collamer aspheric optic; Toric IOL for cataract patients to treat pre-existing astigmatism; and Preloaded Injector, a silicone or acrylic IOL preloaded into a single-use disposable injector. In addition, the company sells surgical products, and other related instruments and devices; and manufactures AquaFlow device for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health maintenance organizations, group purchasing organizations, and government facilities. The company offers its products primarily under the STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow names. It sells products directly through its sales representatives in the United States, Canada, Japan, and Spain, as well as through independent distributors in approximately 60 countries worldwide. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

300 Employees
Last Reported Date: 07/29/15
Founded in 1982

staar surgical co (STAA) Top Compensated Officers

Chief Financial Officer and Vice President
Total Annual Compensation: $303.8K
Chief Accounting Officer and Vice President
Total Annual Compensation: $334.4K
Vice President of Business Development, Corpo...
Total Annual Compensation: $336.2K
Vice President of Global Marketing
Total Annual Compensation: $266.2K
Compensation as of Fiscal Year 2014.

staar surgical co (STAA) Key Developments

STAAR Surgical Company Announces Board Changes

STAAR Surgical Company announced that its Board of Directors has appointed William P. Wall to the Company's Board. Mr. Wall was formerly the General Counsel of Abrams Capital for more than nine years. Mr. Wall is currently a member of the Board of Directors, and chair of the Corporate Governance Committee and member of the Audit Committee, of Haynes International Inc. The company also announced that Charles Slacik has retired from the Board. Mr. Slacik joined the Board in September 2012.

STAAR Surgical Company Appoints Keith Holliday as Vice President Research and Development, Effective August 19, 2015

STAAR Surgical Company has named Keith Holliday Ph.D. to the position of Vice President, Research and Development, effective August 19, 2015. In this position he will lead the company's strategic initiative in building a research and development continuum incorporating STAAR's proprietary Collamer® material and expanding into new areas of opportunity benefiting myopic, presbyopic and cataract vision care lenses and delivery systems. Dr. Holliday's professional career includes his most recent position as Vice President, Research and Development at ReVision Optics where he oversaw the development of their corneal inlay technology that includes a hydrogel inlay for presbyopia correction, delivery devices and clinical methodologies as well as managing first-in-man clinical studies. Previously, he was Director of Laser Technology at Advanced Medical Optics (AMO) and Staff Laser Scientist at VISX.

STAAR Surgical Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended July 3, 2015

STAAR Surgical Company reported unaudited consolidated earnings results for the second quarter and six months ended July 3, 2015. For the quarter, net sales were $18,657,000 against $20,048,000 a year ago. Operating loss was $1,743,000 against $1,390,000 a year ago. Loss before provision for income taxes was $1,446,000 against $1,422,000 a year ago. Net loss was $1,599,000 against $1,789,000 a year ago. Net loss per share - basic and diluted was $0.04 against $0.05 a year ago. Net income - (adjusted) was $167,000 against $291,000 a year ago. Net income per share, basic - (adjusted) was $0.00 against $0.01 a year ago. Net income per share, diluted - (adjusted) was $0.00 against $0.01 a year ago. For the six months, net sales were $37,514,000 against $40,226,000 a year ago. Operating loss was $3,252,000 against $2,732,000 a year ago. Loss before provision for income taxes was $3,812,000 against $2,562,000 a year ago. Net loss was $3,938,000 against $3,148,000 a year ago. Net loss per share - basic and diluted was $0.10 against $0.08 a year ago. Net cash used in operating activities was $1,405,000 against $4,064,000 a year ago. Acquisition of property and equipment was $701,000 against $2,269,000 a year ago. Net income - (adjusted) was $1,154,000 against $1,929,000 a year ago. Net income per share, basic - (adjusted) was $0.03 against $0.05 a year ago. Net income per share, diluted - (adjusted) was $0.03 against $0.05 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STAA:US $7.45 USD -0.15

STAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bovie Medical Corp $2.40 USD +0.11
Ellex Medical Lasers Ltd A$0.38 AUD +0.005
Glaukos Corp $29.90 USD +0.05
IRIDEX Corp $6.88 USD +0.18
Vascular Solutions Inc $33.69 USD -0.46
View Industry Companies
 

Industry Analysis

STAA

Industry Average

Valuation STAA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STAAR SURGICAL CO, please visit www.staar.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.